Faculty Collaboration Database

All Publications for William R. Drobyski MD (159)

Return to online profile of William R. Drobyski MD

• TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. (Runaas L, Fank S, Palen K, Szabo A, Rein L, Ying G, Salzman N, Samanas L, Abedin SM, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters NR, Peled JU, Johnson B, Kearl T, Drobyski WR) Blood Adv 2026 Feb 03 PMID: 41632629 02/03/2026
• Tocilizumab prophylaxis in double cord blood transplantation. (Drobyski WR) Blood Adv 2025 May 27;9(10):2585-2586 PMID: 40423984 PMCID: PMC12235311 Scopus ID: 2-s2.0-105007904022 05/27/2025
• Intestinal epithelium-derived IL-34 reprograms macrophages to mitigate gastrointestinal tract graft-versus-host disease. (Rayasam A, Moe A, Kudek M, Shah RK, Yuan CY, Miller JM, Rau M, Patton M, Wanat K, Colonna M, Zamora AE, Drobyski WR) Sci Transl Med 2025 Feb 12;17(785):eadn3963 PMID: 39937882 PMCID: PMC12771561 Scopus ID: 2-s2.0-85218479788 02/12/2025
• Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease. (Moe A, Rayasam A, Sauber G, Shah RK, Doherty A, Yuan CY, Szabo A, Moore BM 2nd, Colonna M, Cui W, Romero J, Zamora AE, Hillard CJ, Drobyski WR) J Clin Invest 2024 Apr 25;134(11) PMID: 38662453 PMCID: PMC11142740 Scopus ID: 2-s2.0-85195012384 04/25/2024
• Bhlhe40 Promotes CD4+ T Helper 1 Cell and Suppresses T Follicular Helper Cell Differentiation during Viral Infection. (Nguyen C, Kudek M, Zander R, Niu H, Shen J, Bauer A, Alson D, Khatun A, Chen Y, Sun J, Drobyski W, Edelson BT, Cui W) J Immunol 2024 Jun 01;212(11):1829-1842 PMID: 38619295 PMCID: PMC12359248 Scopus ID: 2-s2.0-85194012903 04/15/2024
• Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. (Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M) Bone Marrow Transplant 2024 Mar;59(3):373-379 PMID: 38177221 Scopus ID: 2-s2.0-85181508004 01/05/2024
• Interleukin-9 production by type 2 innate lymphoid cells induces Paneth cell metaplasia and small intestinal remodeling. (Yuan C, Rayasam A, Moe A, Hayward M, Wells C, Szabo A, Mackenzie A, Salzman N, Drobyski WR) Nat Commun 2023 Dec 02;14(1):7963 PMID: 38042840 PMCID: PMC10693577 Scopus ID: 2-s2.0-85178369915 12/03/2023
• Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States. (Lin M, Estrada-Merly N, Eapen M, Zamora AE, Pezzin LE, Winn AN, Philip J, Schinke C, Drobyski WR, Anderson LD Jr, D'Souza A) Bone Marrow Transplant 2023 Dec;58(12):1400-1402 PMID: 37673983 PMCID: PMC11646697 Scopus ID: 2-s2.0-85170080925 09/07/2023
• MICROGLIAL CELL EXPRESSION OF THE TYPE 2 CANNABINOID RECEPTOR REGULATES IMMUNE-MEDIATED NEUROINFLAMMATION. (Moe A, Rayasam A, Sauber G, Shah RK, Yuan CY, Szabo A, Moore BM, Colonna M, Cui W, Romero J, Zamora AE, Hillard CJ, Drobyski WR) bioRxiv 2023 Aug 14 PMID: 37645843 PMCID: PMC10462026 08/30/2023
• Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR) Haematologica 2023 Jan 01;108(1):250-256 PMID: 36106394 PMCID: PMC9827178 Scopus ID: 2-s2.0-85145424654 09/16/2022
• The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation. (Taylor MR, Hillard CJ, Drobyski WR, Szabo A, Johnson BD, Zhu F, Raison CL, Cole SW, Knight JM) Brain Behav Immun Health 2022 Aug;23:100480 PMID: 35757656 PMCID: PMC9213229 Scopus ID: 2-s2.0-85133379996 06/28/2022
• Single-cell immune profiling reveals a developmentally distinct CD4+ GM-CSF+ T-cell lineage that induces GI tract GVHD. (Piper C, Hainstock E, Yin-Yuan C, Chen Y, Khatun A, Kasmani MY, Evans J, Miller JA, Gorski J, Cui W, Drobyski WR) Blood Adv 2022 May 10;6(9):2791-2804 PMID: 35015822 PMCID: PMC9092418 Scopus ID: 2-s2.0-85130140800 01/12/2022
• Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease. (Rayasam A, Drobyski WR) Front Immunol 2021;12:779076 PMID: 34899738 PMCID: PMC8662938 Scopus ID: 2-s2.0-85121218490 12/14/2021
• Toll-like receptor-9 stimulated plasmacytoid dendritic cell precursors suppress autoimmune neuroinflammation in a murine model of multiple sclerosis (Letscher H, Agbogan VA, Korniotis S, Gastineau P, Tejerina E, Gras C, Mégret J, Moe A, Drobyski WR, Zavala F) Scientific Reports December 2021;11(1) Scopus ID: 2-s2.0-85101779771 12/01/2021
• Self-Renewing Islet TCF1⁺ CD8 T Cells Undergo IL-27-Controlled Differentiation to Become TCF1^- Terminal Effectors during the Progression of Type 1 Diabetes. (Ciecko AE, Schauder DM, Foda B, Petrova G, Kasmani MY, Burns R, Lin CW, Drobyski WR, Cui W, Chen YG) J Immunol 2021 Oct 15;207(8):1990-2004 PMID: 34507949 PMCID: PMC8492517 Scopus ID: 2-s2.0-85116529072 09/12/2021
• Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. (Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M) Clin Lymphoma Myeloma Leuk 2021 Oct;21(10):e775-e781 PMID: 34257042 Scopus ID: 2-s2.0-85110347842 07/15/2021
• Toll-like receptor-9 stimulated plasmacytoid dendritic cell precursors suppress autoimmune neuroinflammation in a murine model of multiple sclerosis. (Letscher H, Agbogan VA, Korniotis S, Gastineau P, Tejerina E, Gras C, Mégret J, Moe A, Drobyski WR, Zavala F) Sci Rep 2021 Feb 26;11(1):4735 PMID: 33637789 PMCID: PMC7910458 Scopus ID: 2-s2.0-85101779771 02/28/2021
• The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. (Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR) Transl Psychiatry 2021 Jan 18;11(1):58 PMID: 33462203 PMCID: PMC7812704 Scopus ID: 2-s2.0-85100097244 01/20/2021
• Kras-Deficient T Cells Attenuate Graft-versus-Host Disease but Retain Graft-versus-Leukemia Activity. (Luo L, Chen Y, Chen X, Zheng Y, Zhou V, Yu M, Burns R, Zhu W, Fu G, Felix JC, Hartley C, Damnernsawad A, Zhang J, Wen R, Drobyski WR, Gao C, Wang D) J Immunol 2020 Dec 15;205(12):3480-3490 PMID: 33158956 PMCID: PMC7955895 Scopus ID: 2-s2.0-85097490484 11/08/2020
• Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease. (Yuan CY, Zhou V, Sauber G, Stollenwerk T, Komorowski R, López A, Tolón RM, Romero J, Hillard CJ, Drobyski WR) Blood 2021 Mar 04;137(9):1241-1255 PMID: 33027805 PMCID: PMC7933769 Scopus ID: 2-s2.0-85101859000 10/08/2020
• Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells. (Sarott RC, Westphal MV, Pfaff P, Korn C, Sykes DA, Gazzi T, Brennecke B, Atz K, Weise M, Mostinski Y, Hompluem P, Koers E, Miljuš T, Roth NJ, Asmelash H, Vong MC, Piovesan J, Guba W, Rufer AC, Kusznir EA, Huber S, Raposo C, Zirwes EA, Osterwald A, Pavlovic A, Moes S, Beck J, Benito-Cuesta I, Grande T, Ruiz de Martı N Esteban S, Yeliseev A, Drawnel F, Widmer G, Holzer D, van der Wel T, Mandhair H, Yuan CY, Drobyski WR, Saroz Y, Grimsey N, Honer M, Fingerle J, Gawrisch K, Romero J, Hillard CJ, Varga ZV, van der Stelt M, Pacher P, Gertsch J, McCormick PJ, Ullmer C, Oddi S, Maccarrone M, Veprintsev DB, Nazaré M, Grether U, Carreira EM) J Am Chem Soc 2020 Oct 07;142(40):16953-16964 PMID: 32902974 Scopus ID: 2-s2.0-85092682450 09/10/2020
• Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 Scopus ID: 2-s2.0-85089134303 07/13/2020
• Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 Scopus ID: 2-s2.0-85080146585 01/27/2020
• Pathogenic Bhlhe40+ GM-CSF+ CD4+ T cells promote indirect alloantigen presentation in the GI tract during GVHD. (Piper C, Zhou V, Komorowski R, Szabo A, Vincent B, Serody J, Alegre ML, Edelson BT, Taneja R, Drobyski WR) Blood 2020 Feb 20;135(8):568-581 PMID: 31880771 PMCID: PMC7033370 Scopus ID: 2-s2.0-85081142993 12/28/2019
• Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. (Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A) Amyloid 2019 Dec;26(4):210-215 PMID: 31347424 Scopus ID: 2-s2.0-85074118154 07/28/2019
• Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 Aug;25(8):1689-1694 PMID: 30965140 Scopus ID: 2-s2.0-85065022222 04/10/2019
• Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease. (Piper C, Drobyski WR) Front Immunol 2019;10:163 PMID: 30853956 PMCID: PMC6395399 Scopus ID: 2-s2.0-85062722237 03/12/2019
• The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. (Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V) Blood Adv 2019 Feb 26;3(4):670-680 PMID: 30808685 PMCID: PMC6391668 Scopus ID: 2-s2.0-85062250569 02/28/2019
• Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 Apr;25(4):827-833 PMID: 30572109 Scopus ID: 2-s2.0-85059680507 12/21/2018
• Single-cell RNA sequencing unveils an IL-10-producing helper subset that sustains humoral immunity during persistent infection. (Xin G, Zander R, Schauder DM, Chen Y, Weinstein JS, Drobyski WR, Tarakanova V, Craft J, Cui W) Nat Commun 2018 Nov 28;9(1):5037 PMID: 30487586 PMCID: PMC6261948 Scopus ID: 2-s2.0-85057571059 11/30/2018
• Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. (Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN) Biol Blood Marrow Transplant 2019 Jan;25(1):e33-e38 PMID: 30244105 Scopus ID: 2-s2.0-85055445894 09/24/2018
• Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. (Ganetsky A, Frey NV, Hexner EO, Loren AW, Gill SI, Luger SM, Mangan JK, Martin ME, Babushok DV, Drobyski WR, Smith J, Timlin C, Freyer CW, Stadtmauer EA, Porter DL) Bone Marrow Transplant 2019 Feb;54(2):212-217 PMID: 29795429 Scopus ID: 2-s2.0-85047331089 05/26/2018
• Bim regulates the survival and suppressive capability of CD8⁺ FOXP3⁺ regulatory T cells during murine GVHD. (Agle K, Vincent BG, Piper C, Belle L, Zhou V, Shlomchik W, Serody JS, Drobyski WR) Blood 2018 Jul 26;132(4):435-447 PMID: 29769260 PMCID: PMC6071561 Scopus ID: 2-s2.0-85051830050 05/18/2018
• A model of TH17-associated ileal hyperplasia that requires both IL-17A and IFNγ to generate self-tolerance and prevent colitis. (Jeschke JC, Mayne CG, Ziegelbauer J, DeCiantis CL, Singh S, Kumar SN, Suchi M, Iwakura Y, Drobyski WR, Salzman NH, Williams CB) Mucosal Immunol 2018 Jul;11(4):1127-1137 PMID: 29728642 PMCID: PMC6571016 Scopus ID: 2-s2.0-85046438531 05/08/2018
• Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. (Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2018 Aug;24(8):1664-1670 PMID: 29680516 Scopus ID: 2-s2.0-85047194888 04/24/2018
• Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. (Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A) Bone Marrow Transplant 2018 Sep;53(9):1210-1213 PMID: 29679076 Scopus ID: 2-s2.0-85045751124 04/22/2018
• Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. (Pan P, Oshima K, Huang YW, Agle KA, Drobyski WR, Chen X, Zhang J, Yearsley MM, Yu J, Wang LS) Int J Cancer 2018 Aug 15;143(4):886-896 PMID: 29524208 PMCID: PMC6041131 Scopus ID: 2-s2.0-85044521158 03/11/2018
• Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. (Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M) Haematologica 2018 Apr;103(4):717-727 PMID: 29351985 PMCID: PMC5865423 Scopus ID: 2-s2.0-85044420638 01/21/2018
• Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. (Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR) Biol Blood Marrow Transplant 2017 Nov;23(11):1955-1960 PMID: 28757436 Scopus ID: 2-s2.0-85028446880 08/02/2017
• Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD. (Belle L, Zhou V, Stuhr KL, Beatka M, Siebers EM, Knight JM, Lawlor MW, Weaver C, Hashizume M, Hillard CJ, Drobyski WR) JCI Insight 2017 Jul 20;2(14) PMID: 28724796 PMCID: PMC5518565 Scopus ID: 2-s2.0-85033974707 07/21/2017
• Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 Scopus ID: 2-s2.0-85026445343 07/13/2017
• Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 Scopus ID: 2-s2.0-85019639994 04/17/2017
• Immune reconstitution and tolerance (Belle L, Drobyski WR) Clinical Manual of Blood and Bone Marrow Transplantation 1 January 2017:304-314 Scopus ID: 2-s2.0-85167747117 01/01/2017
• Graft-versus-leukemia effect of allogeneic bone marrow transplantation: Clinical and experimental aspects of late leukemia relapse (Truitt RL, Horowitz MM, Atasoylu AA, Drobyski WR, Johnson BD, LeFever AV) Cellular Immune Mechanisms and Tumor Dormancy 1 January 2017:111-132 Scopus ID: 2-s2.0-1842343134 01/01/2017
• Loss of free fatty acid receptor 2 enhances colonic adenoma development and reduces the chemopreventive effects of black raspberries in ApcMin/+ mice. (Pan P, W Skaer C, Wang HT, Oshima K, Huang YW, Yu J, Zhang J, M Yearsley M, A Agle K, R Drobyski W, Chen X, Wang LS) Carcinogenesis 2017 Jan;38(1):86-93 PMID: 27866157 PMCID: PMC5219051 Scopus ID: 2-s2.0-85027864388 11/21/2016
• Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. (Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M) Bone Marrow Transplant 2016 Dec;51(12):1602-1604 PMID: 27595288 Scopus ID: 2-s2.0-84991038636 09/07/2016
• Effects of Donor Vitamin A Deficiency and Pharmacologic Modulation of Donor T Cell Retinoic Acid Pathway on the Severity of Experimental Graft-versus-Host Disease. (Dodge J, Stephans A, Lai J, Drobyski WR, Chen X) Biol Blood Marrow Transplant 2016 Dec;22(12):2141-2148 PMID: 27596131 Scopus ID: 2-s2.0-85003032776 09/07/2016
• A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease. (Zhou V, Agle K, Chen X, Beres A, Komorowski R, Belle L, Taylor C, Zhu F, Haribhai D, Williams CB, Verbsky J, Blumenschein W, Sadekova S, Bowman E, Ballantyne C, Weaver C, Serody DA, Vincent B, Serody J, Cua DJ, Drobyski WR) J Clin Invest 2016 Sep 01;126(9):3541-55 PMID: 27500496 PMCID: PMC5004941 Scopus ID: 2-s2.0-84987784902 08/09/2016
• Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression. (Belle L, Agle K, Zhou V, Yin-Yuan C, Komorowski R, Eastwood D, Logan B, Sun J, Ghilardi N, Cua D, Williams CB, Gaignage M, Marillier R, van Snick J, Drobyski WR) Blood 2016 Oct 20;128(16):2068-2082 PMID: 27488350 PMCID: PMC5073185 Scopus ID: 2-s2.0-84992051377 08/05/2016
• Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. (Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M) Bone Marrow Transplant 2017 Jan;52(1):147-150 PMID: 27479688 Scopus ID: 2-s2.0-84980370503 08/02/2016
• Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. (Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG, Schultz K, Müller CR, Fernandez-Viña MA, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ) Haematologica 2016 Oct;101(10):1267-1274 PMID: 27247320 PMCID: PMC5046657 Scopus ID: 2-s2.0-84989295930 06/02/2016
• Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 Scopus ID: 2-s2.0-84965053091 05/11/2016
• DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. (Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ) Case Rep Med 2016;2016:8503275 PMID: 26941799 PMCID: PMC4749780 03/05/2016
• Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. (Cornell RF, Hari P, Drobyski WR) Biol Blood Marrow Transplant 2015 Dec;21(12):2061-2068 PMID: 26327628 PMCID: PMC4639405 Scopus ID: 2-s2.0-84947416879 09/04/2015
• Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 Scopus ID: 2-s2.0-84934862607 04/29/2015
• Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. (Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS) Bone Marrow Transplant 2015 Jul;50(7):947-53 PMID: 25867651 PMCID: PMC4490016 Scopus ID: 2-s2.0-84934795677 04/14/2015
• Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ, Graft-vs-Host Disease Working Committee of the CIBMTR) Biol Blood Marrow Transplant 2015 Feb;21(2):266-74 PMID: 25445023 PMCID: PMC4326247 Scopus ID: 2-s2.0-84920903701 12/03/2014
• Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 PMID: 25111581 Scopus ID: 2-s2.0-84912142377 08/12/2014
• Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. (Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN) Biol Blood Marrow Transplant 2014 Mar;20(3):402-408.e1 PMID: 24342394 PMCID: PMC3961011 Scopus ID: 2-s2.0-84896811241 12/18/2013
• Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. (Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ) Leukemia 2014 Mar;28(3):658-65 PMID: 23989431 PMCID: PMC3951192 Scopus ID: 2-s2.0-84895798872 08/31/2013
• Role of Th17 Cells and Interleukin 17 in Graft-versus-host Disease and Graft-versus-leukemia Reactivity (Chen X, Drobyski WR) Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation 2013:271-297 Scopus ID: 2-s2.0-84882596384 08/27/2013
• Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. (Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR) Biol Blood Marrow Transplant 2013 Sep;19(9):1368-73 PMID: 23806770 Scopus ID: 2-s2.0-84882809747 06/29/2013
• The role of regulatory T cells in the biology of graft versus host disease. (Beres AJ, Drobyski WR) Front Immunol 2013;4:163 PMID: 23805140 PMCID: PMC3690651 06/28/2013
• A critical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease. (Chen X, Dodge J, Komorowski R, Drobyski WR) Blood 2013 May 09;121(19):3970-80 PMID: 23529927 PMCID: PMC3650708 Scopus ID: 2-s2.0-84880458648 03/27/2013
• Salvage second hematopoietic cell transplantation in myeloma. (Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2013 May;19(5):760-6 PMID: 23298856 PMCID: PMC3816739 Scopus ID: 2-s2.0-84876327529 01/10/2013
• Role of Th17 cells and interleukin 17 in graft-versus-host disease and graft-versus-leukemia reactivity (Chen X, Drobyski WR) Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation Models in Discovery and Translation 6 December 2012:271-297 Scopus ID: 2-s2.0-85135549834 12/06/2012
• CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. (Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR) J Immunol 2012 Jul 01;189(1):464-74 PMID: 22649199 PMCID: PMC3381996 Scopus ID: 2-s2.0-84862901878 06/01/2012
• Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease. (Rangarajan H, Yassai M, Subramanian H, Komorowski R, Whitaker M, Gorski J, Drobyski WR) Blood 2012 Jun 28;119(26):6354-64 PMID: 22496151 PMCID: PMC3383195 Scopus ID: 2-s2.0-84863508785 04/13/2012
• HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies. (Battiwalla M, Ellis K, Li P, Pavletic SZ, Akpek G, Hematti P, Klumpp TR, Maziarz RT, Savani BN, Aljurf MD, Cairo MS, Drobyski WR, George B, Hahn T, Khera N, Litzow MR, Loren AW, Saber W, Arora M, Urbano-Ispizua A, Cutler C, Flowers ME, Spellman SR) Biol Blood Marrow Transplant 2012 Aug;18(8):1302-8 PMID: 22414493 PMCID: PMC3580851 Scopus ID: 2-s2.0-84863996073 03/15/2012
• Surgical resection as definitive treatment for refractory GVHD of the colon. (Cornell RF, Palmer J, Komorowski R, Drobyski WR) Bone Marrow Transplant 2012 Oct;47(10):1366-7 PMID: 22327134 Scopus ID: 2-s2.0-84867400626 02/14/2012
• T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. (Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J) Biol Blood Marrow Transplant 2012 Jun;18(6):937-43 PMID: 22155505 PMCID: PMC3319849 Scopus ID: 2-s2.0-84862796459 12/14/2011
• Tocilizumab for the treatment of steroid refractory graft-versus-host disease. (Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P) Biol Blood Marrow Transplant 2011 Dec;17(12):1862-8 PMID: 21745454 PMCID: PMC3716013 Scopus ID: 2-s2.0-81255163590 07/13/2011
• Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. (Beres A, Komorowski R, Mihara M, Drobyski WR) Clin Cancer Res 2011 Jun 15;17(12):3969-83 PMID: 21558402 PMCID: PMC3117905 Scopus ID: 2-s2.0-79959268660 05/12/2011
• Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. (Hallett WH, Jing W, Drobyski WR, Johnson BD) Biol Blood Marrow Transplant 2011 Aug;17(8):1133-45 PMID: 21536144 Scopus ID: 2-s2.0-79960218752 05/04/2011
• Gastrointestinal pathology of autologous graft-versus-host disease following hematopoietic stem cell transplantation: a clinicopathological study of 17 cases. (Cogbill CH, Drobyski WR, Komorowski RA) Mod Pathol 2011 Jan;24(1):117-25 PMID: 20953169 Scopus ID: 2-s2.0-78650859518 10/19/2010
• Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. (Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, Drobyski WR) Blood 2010 Jun 24;115(25):5249-58 PMID: 20382845 PMCID: PMC2892952 Scopus ID: 2-s2.0-77954687870 04/13/2010
• Robert Truitt tribute. (Johnson B, Drobyski W, Blazar B, Korngold R) Biol Blood Marrow Transplant 2010 Jan;16(1):143-4 PMID: 19836456 Scopus ID: 2-s2.0-77949880015 10/20/2009
• Immune reconstitution: how it should work, what's broken, and why it matters. (Gress RE, Emerson SG, Drobyski WR) Biol Blood Marrow Transplant 2010 Jan;16(1 Suppl):S133-7 PMID: 19819340 PMCID: PMC2832716 Scopus ID: 2-s2.0-77953074174 10/13/2009
• Interleukin 17 is not required for autoimmune-mediated pathologic damage during chronic graft-versus-host disease. (Chen X, Das R, Komorowski R, van Snick J, Uyttenhove C, Drobyski WR) Biol Blood Marrow Transplant 2010 Jan;16(1):123-8 PMID: 19772944 PMCID: PMC2804961 Scopus ID: 2-s2.0-72649088089 09/24/2009
• Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease. (Filicko-O'Hara J, Grosso D, Flomenberg PR, Friedman TM, Brunner J, Drobyski W, Ferber A, Kakhniashvili I, Keever-Taylor C, Mookerjee B, Talano JA, Wagner JI, Korngold R, Flomenberg N) Biol Blood Marrow Transplant 2009 Dec;15(12):1609-19 PMID: 19744572 PMCID: PMC2783272 Scopus ID: 2-s2.0-70350459268 09/12/2009
• Posterior reversible encephalopathy syndrome as a consequence of high dose steroid administration after autologous PBSCT. (Sukumaran S, George B, Nair HP, Drobyski WR) Bone Marrow Transplant 2010 Apr;45(4):779-80 PMID: 19684634 Scopus ID: 2-s2.0-77950629302 08/18/2009
• Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. (Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, Drobyski WR) Blood 2009 Jul 23;114(4):891-900 PMID: 19491393 PMCID: PMC2716024 Scopus ID: 2-s2.0-68249160054 06/06/2009
• Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. (Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR) Blood 2009 Mar 05;113(10):2352-62 PMID: 19059877 PMCID: PMC2652376 Scopus ID: 2-s2.0-63849105635 12/09/2008
• Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. (Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W) Bone Marrow Transplant 2009 Jan;43(2):169-77 PMID: 18762759 Scopus ID: 2-s2.0-59549095162 09/03/2008
• Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. (Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz MM, Collins R Jr) Bone Marrow Transplant 2008 Aug;42(3):201-5 PMID: 18490913 Scopus ID: 2-s2.0-50049106424 05/21/2008
• Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. (Cohen EP, Irving AA, Drobyski WR, Klein JP, Passweg J, Talano JA, Juckett MB, Moulder JE) Int J Radiat Oncol Biol Phys 2008 Apr 01;70(5):1546-51 PMID: 18029109 PMCID: PMC2386758 Scopus ID: 2-s2.0-40949138809 11/22/2007
• Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. (Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR) Blood 2007 Nov 15;110(10):3804-13 PMID: 17693581 PMCID: PMC2077325 Scopus ID: 2-s2.0-36348980530 08/19/2007
• Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. (Cohen EP, Drobyski WR, Moulder JE) Bone Marrow Transplant 2007 May;39(9):571-2 PMID: 17351643 Scopus ID: 2-s2.0-34247401041 03/14/2007
• Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. (Gorski J, Chen X, Gendelman M, Yassai M, Krueger A, Tivol E, Logan B, Komorowski R, Vodanovic-Jankovic S, Drobyski WR) Blood 2007 Jun 15;109(12):5502-10 PMID: 17347406 PMCID: PMC1890817 Scopus ID: 2-s2.0-34249979259 03/10/2007
• Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection. (Vodanovic-Jankovic S, Drobyski WR) Biol Blood Marrow Transplant 2006 Nov;12(11):1125-34 PMID: 17085305 PMCID: PMC1679815 Scopus ID: 2-s2.0-33750514202 11/07/2006
• NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. (Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR) Blood 2006 Jan 15;107(2):827-34 PMID: 16174760 PMCID: PMC1895627 Scopus ID: 2-s2.0-30444458109 09/22/2005
• Emergent autoimmunity in graft-versus-host disease. (Tivol E, Komorowski R, Drobyski WR) Blood 2005 Jun 15;105(12):4885-91 PMID: 15746077 PMCID: PMC1894995 Scopus ID: 2-s2.0-20444362731 03/05/2005
• Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity? (Hari P, Logan B, Drobyski WR) Biol Blood Marrow Transplant 2004 Nov;10(11):743-7 PMID: 15505605 Scopus ID: 2-s2.0-6444236370 10/27/2004
• The role of allogeneic transplantation in high-risk acute myelogenous leukemia. (Drobyski WR) Leukemia 2004 Oct;18(10):1565-8 PMID: 15452588 Scopus ID: 2-s2.0-6244309270 09/29/2004
• Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration. (Gendelman M, Halligan N, Komorowski R, Logan B, Murphy WJ, Blazar BR, Pritchard KA Jr, Drobyski WR) Blood 2005 Jan 01;105(1):428-31 PMID: 15331451 Scopus ID: 2-s2.0-11144225851 08/28/2004
• Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. (Gendelman M, Hecht T, Logan B, Vodanovic-Jankovic S, Komorowski R, Drobyski WR) J Immunol 2004 Mar 01;172(5):3328-36 PMID: 14978141 Scopus ID: 2-s2.0-1342345057 02/24/2004
• Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. (Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR) Biol Blood Marrow Transplant 2003 Dec;9(12):742-52 PMID: 14677113 Scopus ID: 2-s2.0-0742323844 12/17/2003
• Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. (Burt RK, Drobyski WR, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Stefka J, Kuzel TM, Brush M, Rodriquez J, Burns W, Tennant L, Link C) Exp Hematol 2003 Oct;31(10):903-10 PMID: 14550806 Scopus ID: 2-s2.0-0141596016 10/11/2003
• Concurrent presence of both patient and donor t(14;18) in a follicular lymphoma patient after undergoing allogeneic BMT: implications for minimal residual disease detection post-transplant. (Rosenblum MD, Drobyski WR, Keever-Taylor C, Chang CC) Bone Marrow Transplant 2003 May;31(10):947-9 PMID: 12748676 Scopus ID: 2-s2.0-0037607364 05/16/2003
• Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation. (Drobyski WR, Gendelman M, Vodanovic-Jankovic S, Gorski J) J Immunol 2003 Mar 15;170(6):3046-53 PMID: 12626559 Scopus ID: 2-s2.0-0037443557 03/11/2003
• Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. (Drobyski WR, Gendelman M) Leuk Lymphoma 2002 Oct;43(10):2011-6 PMID: 12481900 Scopus ID: 2-s2.0-0036786652 12/17/2002
• Role of the passive apoptotic pathway in graft-versus-host disease. (Drobyski WR, Komorowski R, Logan B, Gendelman M) J Immunol 2002 Aug 01;169(3):1626-33 PMID: 12133993 Scopus ID: 2-s2.0-0036681957 07/23/2002
• Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. (Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 2002 Feb 01;99(3):806-14 PMID: 11806980 Scopus ID: 2-s2.0-0036464655 01/25/2002
• Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. (Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, Collins RH Jr) J Clin Oncol 2002 Jan 15;20(2):405-12 PMID: 11786567 Scopus ID: 2-s2.0-0037080121 01/12/2002
• Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. (Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR) Biol Blood Marrow Transplant 2001;7(11):620-30 PMID: 11760150 Scopus ID: 2-s2.0-0034747266 01/05/2002
• Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. (Drobyski WR, Morse HC 3rd, Burns WH, Casper JT, Sandford G) Blood 2001 Apr 15;97(8):2506-13 PMID: 11290616 Scopus ID: 2-s2.0-0035871695 04/06/2001
• Donor leukocyte infusions for multiple myeloma. (Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, Porter D, Giralt S, Levine JE, Drobyski W, Barrett AJ, Horowitz M, Collins RH) Bone Marrow Transplant 2000 Dec;26(11):1179-84 PMID: 11149728 Scopus ID: 2-s2.0-0033665539 01/10/2001
• Quantitative evaluation of post-bone marrow transplant engraftment status using fluorescent-labeled variable number of tandem repeats. (Luhm RA, Bellissimo DB, Uzgiris AJ, Drobyski WR, Hessner MJ) Mol Diagn 2000 Jun;5(2):129-38 PMID: 11066014 Scopus ID: 2-s2.0-0033920852 11/07/2000
• Donor leukocyte infusions in acute lymphocytic leukemia. (Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M, Parker P) Bone Marrow Transplant 2000 Sep;26(5):511-6 PMID: 11019840 Scopus ID: 2-s2.0-0033832579 10/06/2000
• Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice. (Drobyski WR, Vodanovic-Jankovic S, Klein J) J Immunol 2000 Aug 01;165(3):1634-40 PMID: 10903774 Scopus ID: 2-s2.0-0034254303 07/21/2000
• Evolving strategies to address adverse transplant outcomes associated with T cell depletion. (Drobyski WR) J Hematother Stem Cell Res 2000 Jun;9(3):327-37 PMID: 10894354 Scopus ID: 2-s2.0-0033945340 07/14/2000
• T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. (Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringdén O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM) Blood 2000 Jun 15;95(12):3996-4003 PMID: 10845940 Scopus ID: 2-s2.0-18844467941 06/14/2000
• Adoptive immunotherapy using donor leukocyte infusions to treat relapsed hematologic malignancies after allogeneic bone marrow transplantation. (Drobyski WR) Cancer Treat Res 1999;101:233-66 PMID: 10800652 Scopus ID: 2-s2.0-0033290494 05/09/2000
• Erratum: T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation (Blood (July 15, 199) 94 (434-441)) (Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 15 February 2000;95(4):1137 Scopus ID: 2-s2.0-0034651814 02/15/2000
• Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. (Porter DL, Collins RH Jr, Hardy C, Kernan NA, Drobyski WR, Giralt S, Flowers ME, Casper J, Leahey A, Parker P, Mick R, Bate-Boyle B, King R, Antin JH) Blood 2000 Feb 15;95(4):1214-21 PMID: 10666193 Scopus ID: 2-s2.0-0034651931 02/09/2000
• Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes. (Burt RK, Drobyski WR, Traynor AE, Link CJ Jr) Bone Marrow Transplant 1999 Nov;24(10):1043-51 PMID: 10578153 Scopus ID: 2-s2.0-0032732523 12/01/1999
• Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. (Drobyski WR, Majewski D, Hanson G) Biol Blood Marrow Transplant 1999;5(4):222-30 PMID: 10465102 Scopus ID: 2-s2.0-0032610496 08/28/1999
• Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. (Porter DL, Collins RH Jr, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH) Biol Blood Marrow Transplant 1999;5(4):253-61 PMID: 10465105 Scopus ID: 2-s2.0-0032605618 08/28/1999
• T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. (Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 1999 Jul 15;94(2):434-41 PMID: 10397710 Scopus ID: 2-s2.0-0033566306 07/09/1999
• The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. (Drobyski WR, Hessner MJ) Leuk Lymphoma 1998 Oct;31(3-4):317-23 PMID: 9869195 Scopus ID: 2-s2.0-0032425748 12/30/1998
• Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. (Drobyski WR, Majewski D, Ozker K, Hanson G) J Immunol 1998 Sep 01;161(5):2610-9 PMID: 9725263 Scopus ID: 2-s2.0-0032168558 09/02/1998
• Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. (Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, Keever-Taylor CA) Biol Blood Marrow Transplant 1998;4(1):3-12 PMID: 9701386 Scopus ID: 2-s2.0-0031615090 08/13/1998
• T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. (Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D) Bone Marrow Transplant 1998 May;21(9):893-9 PMID: 9613781 Scopus ID: 2-s2.0-0031894170 06/05/1998
• Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. (Lawton CA, Cohen EP, Murray KJ, Derus SW, Casper JT, Drobyski WR, Horowitz MM, Moulder JE) Bone Marrow Transplant 1997 Dec;20(12):1069-74 PMID: 9466280 Scopus ID: 2-s2.0-0031437525 02/18/1998
• Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103. (Link CJ Jr, Burt RK, Traynor AE, Drobyski WR, Seregina T, Levy JP, Gordon L, Rosen ST, Burns WH, Camitta B, Casper J, Horowitz M, Juckett M, Lawton C, Margolis D, Pietryga D, Rowlings P, Taylor C, Furtado M, Stefka J, Gupta-Burt S, Kaiser H, Vesole DH) Hum Gene Ther 1998 Jan 01;9(1):115-34 PMID: 9458247 Scopus ID: 2-s2.0-0031975258 02/11/1998
• Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. (Drobyski WR, Endean DJ, Klein JP, Hessner MJ) Br J Haematol 1997 Aug;98(2):458-66 PMID: 9266951 Scopus ID: 2-s2.0-0030873760 08/01/1997
• Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. (Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M, Margolis D, Flomenberg N, Keever-Taylor CA) Bone Marrow Transplant 1997 Jun;19(11):1069-77 PMID: 9193748 Scopus ID: 2-s2.0-0030982179 06/01/1997
• Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J) J Clin Oncol 1997 Feb;15(2):433-44 PMID: 9053463 02/01/1997
• Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice. (Drobyski WR, Majewski D) Blood 1997 Feb 01;89(3):1100-9 PMID: 9028343 Scopus ID: 2-s2.0-0030893727 02/01/1997
• Modulation of in vitro and in vivo T-cell responses by transferrin-gallium and gallium nitrate. (Drobyski WR, Ul-Haq R, Majewski D, Chitambar CR) Blood 1996 Oct 15;88(8):3056-64 PMID: 8874204 Scopus ID: 2-s2.0-0029859282 10/15/1996
• Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. (Drobyski WR, Majewski D) Blood 1996 Jun 15;87(12):5355-69 PMID: 8652851 Scopus ID: 2-s2.0-0029954330 06/15/1996
• Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. (Drobyski WR, Potluri J, Sauer D, Gottschall JL) Bone Marrow Transplant 1996 Jun;17(6):1093-9 PMID: 8807120 Scopus ID: 2-s2.0-0030037577 06/01/1996
• Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. (Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR) Blood 1995 Nov 15;86(10):3987-96 PMID: 7579370 Scopus ID: 2-s2.0-0028856613 11/15/1995
• Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. (Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Camitta B, Lawton C) Bone Marrow Transplant 1995 Aug;16(2):271-5 PMID: 7581147 Scopus ID: 2-s2.0-0029150064 08/01/1995
• Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. (Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F) Blood 1995 May 01;85(9):2354-63 PMID: 7727769 Scopus ID: 2-s2.0-0028921178 05/01/1995
• Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients. (Baxter-Lowe LA, Keever C, Dinauer D, Daniels T, Johnson K, Camitta B, Drobyski W, Garbrecht F, Horowitz M, Pietryga D) Transplant Proc 1995 Feb;27(1):1377-8 PMID: 7878917 Scopus ID: 2-s2.0-0028804487 02/01/1995
• Ganciclovir strategies after marrow transplantation (Goodrich JM, Zaia JA, Boeckh M, Bowden RA, Carrigan DR, Knox KK, Drobyski WR) Bone Marrow Transplantation 1995;15(SUPPL. 1):S156-S161 Scopus ID: 2-s2.0-0029025566 01/01/1995
• Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival, and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. (Drobyski WR, Keever CA, Hanson GA, McAuliffe T, Griffith OW) Blood 1994 Oct 01;84(7):2363-73 PMID: 7522627 Scopus ID: 2-s2.0-0027965550 10/01/1994
• Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. (Drobyski WR, Knox KK, Majewski D, Carrigan DR) N Engl J Med 1994 May 12;330(19):1356-60 PMID: 8152447 Scopus ID: 2-s2.0-0028266188 05/12/1994
• Increasing incidence of adenovirus disease in bone marrow transplant recipients. (Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV, McAuliffe T, Camitta B, Horowitz MM, Bunin N) J Infect Dis 1994 Apr;169(4):775-81 PMID: 8133091 Scopus ID: 2-s2.0-0028256278 04/01/1994
• Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. (Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F) Blood 1994 Apr 01;83(7):1980-7 PMID: 8142664 Scopus ID: 2-s2.0-0028179358 04/01/1994
• Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. (Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS) J Clin Oncol 1994 Mar;12(3):475-82 PMID: 7509852 Scopus ID: 2-s2.0-0028223380 03/01/1994
• Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. (Hessner MJ, Roth MS, Drobyski WR, Baxter-Lowe LA) Genet Anal Tech Appl 1994;11(4):90-4 PMID: 7857690 Scopus ID: 2-s2.0-0028251004 01/01/1994
• Component processing and intraoperative autotransfusion during bone marrow harvest. (Cook-Craig A, Owen A, Reeder G, Drobyski W, Horowitz M, Brunner J, Flomenberg N, Keever C) Prog Clin Biol Res 1994;389:613-9 PMID: 7700927 Scopus ID: 2-s2.0-0028720394 01/01/1994
• Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. (Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM) Blood 1993 Oct 15;82(8):2310-8 PMID: 8400284 Scopus ID: 2-s2.0-0027437385 10/15/1993
• Prevalence of human herpesvirus 6 variant A and B infections in bone marrow transplant recipients as determined by polymerase chain reaction and sequence-specific oligonucleotide probe hybridization. (Drobyski WR, Eberle M, Majewski D, Baxter-Lowe LA) J Clin Microbiol 1993 Jun;31(6):1515-20 PMID: 8391023 PMCID: PMC265570 Scopus ID: 2-s2.0-0027284945 06/01/1993
• Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. (Johnson BD, Drobyski WR, Truitt RL) Bone Marrow Transplant 1993 Apr;11(4):329-36 PMID: 8485480 Scopus ID: 2-s2.0-0027537527 04/01/1993
• Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo. (Drobyski WR, Dunne WM, Burd EM, Knox KK, Ash RC, Horowitz MM, Flomenberg N, Carrigan DR) J Infect Dis 1993 Mar;167(3):735-9 PMID: 8382723 Scopus ID: 2-s2.0-0027458632 03/01/1993
• Detection of residual leukemia by the polymerase chain reaction and sequence-specific oligonucleotide probe hybridization after allogeneic bone marrow transplantation for AKR leukemia: a murine model for minimal residual disease. (Drobyski WR, Baxter-Lowe LA, Truitt RL) Blood 1993 Jan 15;81(2):551-9 PMID: 8422472 Scopus ID: 2-s2.0-0027534244 01/15/1993
• Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. (Drobyski WR, Roth MS, Thibodeau SN, Gottschall JL) Bone Marrow Transplant 1992 Sep;10(3):301-4 PMID: 1422483 Scopus ID: 2-s2.0-0026713583 09/01/1992
• Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4. (Drobyski WR, LeFever AV, Truitt RL) Exp Hematol 1991 Oct;19(9):950-7 PMID: 1716592 Scopus ID: 2-s2.0-0025816631 10/01/1991
• Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. (Carrigan DR, Drobyski WR, Russler SK, Tapper MA, Knox KK, Ash RC) Lancet 1991 Jul 20;338(8760):147-9 PMID: 1677066 Scopus ID: 2-s2.0-0025856771 07/20/1991
• Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. (Drobyski WR, Knox KK, Carrigan DR, Ash RC) Transplantation 1991 Jul;52(1):155-7 PMID: 1650043 Scopus ID: 2-s2.0-0025864269 07/01/1991
• Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. (Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC) Transplantation 1991 Jun;51(6):1190-6 PMID: 1646504 Scopus ID: 2-s2.0-0025854880 06/01/1991
• Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. (Knox KK, Drobyski WR, Carrigan DR) Lancet 1991 May 25;337(8752):1292-3 PMID: 1674092 Scopus ID: 2-s2.0-0025821687 05/25/1991
• Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow. (Drobyski WR, Piaskowski V, Ash RC, Casper JT, Truitt RL) Transplantation 1990 Oct;50(4):625-32 PMID: 1699309 Scopus ID: 2-s2.0-0025001706 10/01/1990
• Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. (Drobyski W, Thibodeau S, Truitt RL, Baxter-Lowe LA, Gorski J, Jenkins R, Gottschall J, Ash RC) Blood 1989 Nov 01;74(6):2285-94 PMID: 2572285 Scopus ID: 2-s2.0-0024448687 11/01/1989
• Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. (Drobyski WR, Qazi R) Am J Hematol 1989 Jun;31(2):138-41 PMID: 2660545 Scopus ID: 2-s2.0-0024381610 06/01/1989
• Estrogen receptors and the pattern of relapse in breast cancer. (Qazi R, Chuang JL, Drobyski W) Arch Intern Med 1984 Dec;144(12):2365-7 PMID: 6508445 Scopus ID: 2-s2.0-0021747586 12/01/1984